Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone617-807-6600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.12 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its quarterly earnings results on Thursday, August, 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.92) by $0.02. The specialty pharmaceutical company earned $0.04 million during the quarter, compared to analysts' expectations of $0.10 million. Paratek Pharmaceuticals had a negative net margin of 656.41% and a negative return on equity of 149.09%. View Paratek Pharmaceuticals' Earnings History.
When is Paratek Pharmaceuticals' next earnings date?
What price target have analysts set for PRTK?
7 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $13.00 to $50.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $24.8571 in the next year. This suggests a possible upside of 330.8% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.
What is the consensus analysts' recommendation for Paratek Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.
What are Wall Street analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "916-3963, Probability of success (POS) Risk-adj value Full value Rating NUZYRA – ABSSSI 100.0% $9.34 $9.34 Shares outstanding 32,285 S/O as of December 31, 2018." (2/28/2019)
- 2. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (2/27/2019)
- 3. LADENBURG THALM/SH SH analysts commented, "We are transferring coverage of Paratek Pharmaceuticals, maintaining a Buy rating and $18 price target. Paratek received FDA approval for two novel antibiotics. Nuzyra (omadacycline) was approved in both acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Additionally, Seysara (sarecycline) was approved for inflammatory acne, with U.S. commercialization exclusively licensed to Rated) (sub- licensed to Not Rated). Paratek retains Seysara’s ex-U.S. rights." (12/18/2018)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
News headlines about PRTK stock have trended neutral this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next few days.
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Cara Therapeutics (CARA), CymaBay Therapeutics (CBAY), Revance Therapeutics (RVNC), Vectura Group (VEGPF), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX), Evolus (EOLS), Magenta Therapeutics (MGTA), DiaMedica Therapeutics (DMCAF), TG Therapeutics (TGTX), Synthorx (THOR), Viking Therapeutics (VKTX) and Aurinia Pharmaceuticals (AUPH).
What other stocks do shareholders of Paratek Pharmaceuticals own?
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 61)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
- Mr. Douglas W. Pagán, Chief Financial Officer (Age 47)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
- Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
Who are Paratek Pharmaceuticals' major shareholders?
Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Norges Bank (1.48%), General American Investors Co. Inc. (1.45%), Northern Trust Corp (1.28%), Water Island Capital LLC (0.99%), Royce & Associates LP (0.99%) and Geode Capital Management LLC (0.96%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Robert S Radie, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Which institutional investors are selling Paratek Pharmaceuticals stock?
PRTK stock was sold by a variety of institutional investors in the last quarter, including Water Island Capital LLC, Royce & Associates LP, Two Sigma Investments LP, Trellus Management Company LLC, Northern Trust Corp, New York State Common Retirement Fund, Wedbush Securities Inc. and Hilltop Holdings Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Thomas John Dietz and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.
Which institutional investors are buying Paratek Pharmaceuticals stock?
PRTK stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Fosun International Ltd, Teton Advisors Inc., Gamco Investors INC. ET AL, Gabelli Funds LLC, Virtu Financial LLC, General American Investors Co. Inc. and Telemetry Investments L.L.C.. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $5.77.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $187.06 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.
What is Paratek Pharmaceuticals' official website?
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
